Clinical trials
Functional Magnetic Resonance Imaging clinical trials
Below are recruiting functional magnetic resonance imaging clinical trials, each written for real people, not researchers. We’re tracking 275 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07042295RecruitingPhase 2
Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07226453RecruitingPhase 2
Metformin for recurrent PFA ependymoma
This trial tests if metformin can help treat a certain type of brain tumor called PFA ependymoma that has come back after surgery and radiation. It's for people ages 1 to 39 who are healthy enough for surgery or have tumors that can be measured on scans.
San Francisco, CaliforniaAges 1–39 - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Tucson, ArizonaAges 18 years+ - NCT06589804RecruitingPhase 3
Testing cetuximab plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Little Rock, ArkansasAges 18 years+ - NCT07215910RecruitingPhase 3
Testing vorasidenib with temozolomide after radiation for advanced brain cancer
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
Duarte, CaliforniaAges 12 years+ - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Jonesboro, ArkansasAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT07602270Recruiting
How a Ketogenic Diet Affects Alcohol in Your Body
This study tests whether eating a ketogenic diet (very low carb, high fat) changes how your body processes alcohol. Researchers will have you follow a special diet and then measure your body's response to controlled amounts of alcohol in a lab setting.
Philadelphia, PennsylvaniaAges 21–50 - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Anchorage, AlaskaAges 18 years+ - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Birmingham, AlabamaAges 18 years+ - NCT07017829RecruitingPhase 2
GT103 plus pembrolizumab for STK11 mutant lung cancer
This trial tests a new drug called GT103 combined with the immunotherapy pembrolizumab (Keytruda) for people with advanced lung cancer that has a specific genetic change (STK11 mutation) and has continued to grow despite prior pembrolizumab treatment. The goal is to see if adding GT103 can help shrink tumors or slow the cancer's growth.
Buffalo, New YorkAges 18 years+ - NCT02316314Recruiting
Study heart scan and function in people with Friedreich’s ataxia
This study uses heart tests (including ultrasound and MRI) to better understand how Friedreich’s ataxia affects the heart. You might benefit by getting detailed heart evaluation and contributing to research that could guide future care.
New York, New YorkAges 12–50 - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Birmingham, AlabamaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT07147231RecruitingPhase 1/Phase 2
Pidnarulex plus cemiplimab for MSS colorectal cancer
This trial tests two drugs together: pidnarulex (a targeted therapy) and cemiplimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced colorectal cancer that is microsatellite stable (MSS) and has not responded to current treatments, especially if their tumor has a MYC or FBXW7 change.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06130826RecruitingPhase 1
Immune therapy and radiation for advanced colorectal or breast cancer
This trial tests a combination of stereotactic body radiation therapy (SBRT) and an immune-boosting drug (M5A-IL2) for colorectal or breast cancer that has spread and is no longer responding to standard treatments. The goal is to activate your immune system to fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT05382338RecruitingPhase 3
Sodium thiosulfate to protect hearing in medulloblastoma
This Phase 3 study tests whether adding sodium thiosulfate during treatment for newly diagnosed medulloblastoma can reduce the risk of hearing loss. It is designed for children and teens whose cancer meets specific low-risk or average-risk tumor and lab features.
Birmingham, AlabamaAges 4–21 - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Birmingham, AlabamaAges 12 months–30 years - NCT03649880RecruitingPhase 2
Testing a special PET scan for brain tumor activity
This trial studies whether a brain PET scan using a medicine called FMISO can help show how active certain brain tumors are. It mainly aims to see if the scan is practical and useful in planning care for people with suspected or known brain tumors.
Portland, OregonAges 18 years+ - NCT03729115Recruiting
Breast cancer risk tracking for women at very high risk
This study checks how well a “multi-step” monitoring plan (mostly imaging and follow-up) can track breast cancer risk early in women who are at high risk. You may qualify if you have certain gene changes or strong risk from family history, breast density, or past radiation.
Chicago, IllinoisAges 25 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT04369560RecruitingEarly Phase 1
Virtual MRI to map bladder cancer for staging before surgery
This early-stage study uses special MRI imaging to create a “virtual view” of the bladder wall so doctors can better stage bladder cancer before treatment. If you qualify, you may get MRI imaging using contrast medicines as part of planning your surgery.
Pittsburgh, PennsylvaniaAges 18–90
Hear when a new Functional Magnetic Resonance Imaging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for functional magnetic resonance imaging?
- Yes. Clin2 currently lists 275 recruiting functional magnetic resonance imaging studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a functional magnetic resonance imaging trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a functional magnetic resonance imaging trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.